ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Abstract: TH-PO1116

Niraparib, an FDA-Approved Poly-(ADP-Ribose) Polymerase (PARP) Inhibitor Is Renoprotective against Cisplatin Nephrotoxicity in Ovarian Tumor-Bearing Mice

Session Information

  • CKD: Mechanisms - 1
    October 24, 2024 | Location: Exhibit Hall, Convention Center
    Abstract Time: 10:00 AM - 12:00 PM

Category: CKD (Non-Dialysis)

  • 2303 CKD (Non-Dialysis): Mechanisms

Authors

  • Noh, Mira, Icahn School of Medicine at Mount Sinai, New York, New York, United States
  • Kannan, Amritha, Icahn School of Medicine at Mount Sinai, New York, New York, United States
  • Padanilam, Babu J., Icahn School of Medicine at Mount Sinai, New York, New York, United States
Background

Cisplatin is one of the most commonly used drugs for the treatment of many solid cancers. However, its dose-limiting side effect is nephrotoxicity, leading to acute kidney injury and chronic kidney disease. We previously demonstrated that genetic or pharmacological suppression of poly(ADP-ribose) polymerase 1 (PARP1) protects against cisplatin nephrotoxicity. PARP1 inhibitors such as olaparib, niraparib, and rucaparib are currently FDA-approved for the treatment of ovarian cancer. In this study, we investigated the effect of niraparib on cisplatin nephrotoxicity in an ovarian tumor-bearing model.

Methods

OVCAR3, ovarian cancer cell line cells, bearing mice were established in athymic nude mice and the animals were treated with saline (vehicle), 8 mg/kg cisplatin (once a week), or cisplatin plus 10 mg/kg niraparib (daily).

Results

We found that PARP1 inhibition attenuated kidney cell death and tissue damage, preserving renal function during cisplatin treatment in ovarian tumor bearing mice. Furthermore, inhibition of PARP1 attenuated cisplatin-induced inflammation and renal interstitial fibrogenesis.

Conclusion

Taken together, these results demonstrate that the FDA-approved PARP inhibitor, niraparib can protect efficaciously against renal tubular cell death during cisplatin nephrotoxicity in tumor bearing mice and could be developed as potential therapeutic agents to improve cisplatin nephrotoxicity.